A groundbreaking development is set to revolutionize the treatment of obesity as public medical insurance will now cover a new drug starting this week. This marks a significant milestone, as it is the first time in three decades that such a treatment has been included in the national health insurance price list. The drug, called Wegovy, is manufactured by Novo Nordisk, a renowned Danish pharmaceutical company.
Wegovy contains semaglutide, an active ingredient that acts as a GLP-1 receptor agonist. This means that it stimulates the body to produce more insulin, leading to lower blood sugar levels. Additionally, Wegovy also triggers a feeling of satiety and reduces cravings, which results in appetite suppression.
The inclusion of Wegovy in public medical insurance offers a remarkable expansion of healthcare options for individuals struggling with obesity. Obesity is a global health concern with a wide range of associated health risks. This development provides new hope for people seeking long-term solutions to manage their weight effectively.
Q: What is Wegovy?
A: Wegovy is a newly-approved drug for obesity treatment containing semaglutide, which stimulates insulin production and induces a feeling of satiety, leading to appetite suppression.
Q: Who manufactures Wegovy?
A: Wegovy is manufactured by Novo Nordisk, a leading Danish pharmaceutical company.
Q: How does Wegovy work?
A: As a GLP-1 receptor agonist, Wegovy stimulates insulin production, lowers blood sugar levels, and reduces cravings, thus promoting weight loss.
Q: How significant is the inclusion of Wegovy in public medical insurance?
A: This marks the first time in three decades that a new treatment for obesity is covered by public medical insurance, expanding healthcare options for individuals struggling with weight management.